Evidence map›Paper›PMID 22517435›Full record

ArticleCancer2012

Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study.

Paige M Bracci, Mi Zhou, Scott Young, Joseph Wiemels

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Immunosignature system for diagnosis of cancer.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Article
  18. Review
  19. Review
  20. Neuropsychiatric Symptoms in Lupus.Psychiatric annals · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Paige M BracciSchool of Medicine, University of California San Francisco, San Francisco, CA 94118-1944, USA. paige.bracci@ucsf.edu
Mi Zhou
Scott Young
Joseph Wiemels
University of California, San Francisco · USUniversity of San Francisco · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
Project 3: Prenatal Exposure, DNA Methylation & Childhood LeukemiaP01ES018172 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI METAYER, CATHERINE · 2009 to 2013
$3.7M
Molecular Epidemiology of Pancreatic CancerR01CA109767 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRACCI, PAIGE M. · 2005 to 2010
$3.2M
Meningioma: Risk Factors and Quality of LifeR01CA109745 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIEMELS, JOSEPH LEO · 2006 to 2010
$1.9M
Pancreas cancer analysis-SF Bay Area case-control studyR03CA108370 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HOLLY, ELIZABETH A. · 2004 to 2005
$152k
MTHFR POLYMORPHISMS IN PANCREATIC CANCER IN SF BAY AREAR03CA089726 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HOLLY, ELIZABETH A. · 2001 to 2002
$148k
PANCREATIC CANCER CASE CONTROL STUDY IN SAN FRANCISCOR01CA059706 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HOLLY, ELIZABETH A. · 1994 to 1998
–
NCI NIH HHS N01 PC035136NCI NIH HHS P50 CA097257NCI NIH HHS P50CA097257NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA059706NCI NIH HHS R01CA1009767NCI NIH HHS R01 CA109745NCI NIH HHS R01CA109745NCI NIH HHS R01 CA109767NCI NIH HHS R01CA109767S1NCI NIH HHS R01CA52689NCI NIH HHS R01CA59706NCI NIH HHS R03 CA089726NCI NIH HHS R03 CA108370NCI NIH HHS R03CA108370NCI NIH HHS R03CA89726NIEHS NIH HHS P01 ES018172NIEHS NIH HHS P01ES018172PHS HHS U55/CCR921930-02
6 · The paper itself

Abstract

backgroundScreening and early diagnosis tools are lacking for pancreatic adenocarcinoma; most patients are diagnosed with metastatic disease. Autoantibodies to tumor-associated antigens (TAAs) can be present months to years before diagnosis and hold promise as biomarkers for early detection.

methodsTAAs to pancreatic cancer autoantibodies CTDSP1 (carboxy-terminal domain, RNA polymerase II, polypeptide A, small phosphatase 1), MAPK9 (mitogen-activated protein kinase 9), and NR2E3 (nuclear receptor subfamily 2, group E, member 3), which were identified as potentially promising biomarkers in exploratory studies, were evaluated in serum from participants (300 cases, 300 controls) in a population-based case-control pancreatic cancer study in the San Francisco Bay Area. Patients were identified through cancer registry rapid case ascertainment, newly diagnosed from 1995 to 1999 and followed up through 2008. Autoantibody levels were analyzed as continuous and grouped (quartiles) variables. Multivariable unconditional logistic regression was used to compute odds ratios (ORs) as estimates of autoantibody levels associated with disease status. Kaplan-Meier product limit estimates and multivariable Cox proportional hazards regression were used to assess autoantibody levels associated with case survival duration.

resultsCases had higher levels of CTDSP1 (P = .004), MAPK9 (P = .0002), and NR2E3 (P ≤ .0001) autoantibodies than controls (fourth vs first quartile: CTDSP1 OR = 1.7, MAPK9 OR = 2.5, NR2E3 OR = 4.0). High body mass index and tobacco use were associated with levels in controls but were not statistical confounders. High CTDSP1 levels were somewhat associated with better survival (hazard ratio = 0.77, P = .07).

conclusionsCombined with previous results, this study contributes evidence that cancer-related host immune-response factors may be useful diagnostic screening tools and prognostic indicators for pancreatic cancer. Further studies are needed to critically assess the value of autoantibody panels to TAAs in diagnostic screening, prognosis, and immunotherapy of pancreatic and other cancers.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmAutoantibodiesBiomarkers, TumorCase-Control StudiesEarly Detection of CancerFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosisSan FranciscoAntigens, NeoplasmAutoantibodiesBiomarkers, Tumor

Identifiers

PMID22517435
PMCPMC3414682
OpenAlexW1523964304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.